Success Metrics

Clinical Success Rate
94.1%

Based on 16 completed trials

Completion Rate
94%(16/17)
Active Trials
14(34%)
Results Posted
13%(2 trials)
Terminated
1(2%)

Phase Distribution

Ph phase_2
2
5%
Ph not_applicable
17
41%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution19 total trials
Phase 2Efficacy & side effects
2(10.5%)
N/ANon-phased studies
17(89.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

88.9%

16 of 18 finished

Non-Completion Rate

11.1%

2 ended early

Currently Active

14

trials recruiting

Total Trials

41

all time

Status Distribution
Active(15)
Completed(16)
Terminated(2)
Other(8)

Detailed Status

Completed16
Recruiting12
unknown8
Active, not recruiting2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
41
Active
14
Success Rate
94.1%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (10.5%)
N/A17 (89.5%)

Trials by Status

recruiting1229%
terminated12%
completed1639%
unknown820%
withdrawn12%
active_not_recruiting25%
enrolling_by_invitation12%

Recent Activity

Clinical Trials (41)

Showing 20 of 41 trialsScroll for more
NCT07518069

Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes

Recruiting
NCT03017573Not Applicable

Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)

Recruiting
NCT06880094Not Applicable

Study of Congenital Orofacial Clefts by Implementing Optical Genome Mapping

Recruiting
NCT07071649Not Applicable

Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers

Recruiting
NCT06880107Not Applicable

Genetic Variants of Annexin A2 and Cryptogenic Stroke

Recruiting
NCT04022161Phase 2

Effects of Prolonged Delivery of Nitric Oxide Gas on Plasma Reduction-Oxidation Reactions in Cardiac Surgical Patients

Withdrawn
NCT06373926Not Applicable

Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome

Recruiting
NCT04201470Not Applicable

Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis

Completed
NCT05962177Not Applicable

Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and Serologic

Recruiting
NCT06870838

Neuroinflammation in FTLD

Active Not Recruiting
NCT06847100

Artificial Intelligence Models to Predict Clinically Relevant Cardiovascular Outcomes

Completed
NCT03727399

Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients

Enrolling By Invitation
NCT06871800

Blood Extracellular Vesicles as Predictive Recovery Biomarker After Stroke and Brain Injury

Recruiting
NCT05370105

Extracellular Vesicles as Stroke Biomarkers

Completed
NCT06113705Not Applicable

Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospective Study.

Recruiting
NCT05754645

The Microbiome in (Non-) Obese Pregnancy and Pregnancy Outcomes

Recruiting
NCT05510596Not Applicable

Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome

Completed
NCT04121065

Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)

Recruiting
NCT06279936

Neurobiological Underpinnings of Neuropsychological Consequences in Long COVID

Active Not Recruiting
NCT03505086

Bleeding In Thrombocytopenia Explained

Recruiting

Drug Details

Intervention Type
GENETIC
Total Trials
41